Related Experiment Video
Updated: Apr 23, 2026
Systemic Treatment for Postnatal, Juvenile, and Runted Adult Mice by Retrobulbar Sinus Injection
Published on: May 17, 2024
Systemic treatment
Maria Reig1, Alessia Gazzola2, Roberto Di Donato2
1Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain.
Abstract:
In the last years the management of patients with liver cancer has been improved. The BCLC staging/treatment strategy identifies the optimal candidates for each treatment option and sorafenib is the only effective systemic treatment. Others (sunitinib, brivanib, linifanib, everolimus, ramucirumab) have failed in terms of safety/survival benefit. Some patients at intermediate/early stage, may be considered for systemic therapy when options of higher priority may have failed or not be feasible. The 800 mg/day is the recommended starting dose. Close follow-up and easy access for the patients so that they can report any adverse event and implement dose adjustments is the key point in the management of them. Development of early dermatologic adverse events has been correlated with better outcome and the pattern of radiologic progression characterizes better the prognosis/outcome of these patients. Treatment beyond progression may be considered if there is no option for a second line research trial.
Insights
Sorafenib is the primary systemic treatment for liver cancer, with careful monitoring and dose adjustment crucial for patient outcomes. Early side effects and imaging patterns predict prognosis, with treatment continuation considered post-progression.
Area of Science:
- Hepatology
- Medical Oncology
- Clinical Therapeutics
Background:
- Liver cancer management has advanced, with the Barcelona Clinic Liver Cancer (BCLC) strategy guiding treatment.
- Sorafenib remains the sole validated systemic therapy demonstrating efficacy.
Purpose of the Study:
- To review the current management strategies for liver cancer patients.
- To highlight the role of sorafenib and patient monitoring in optimizing outcomes.
Main Methods:
- Review of current clinical guidelines and therapeutic options for liver cancer.
- Analysis of sorafenib's efficacy, safety profile, and dosing recommendations.
- Discussion of prognostic indicators and treatment beyond progression.
Main Results:
- Sorafenib is the established first-line systemic treatment; other agents have shown limited benefit.
- Close patient follow-up and proactive management of adverse events, particularly dermatologic ones, correlate with better outcomes.
- Radiologic progression patterns offer prognostic insights.
Conclusions:
- The BCLC strategy effectively guides liver cancer treatment selection.
- Sorafenib, with appropriate dose management and monitoring, is key for systemic therapy.
- Prognostic factors and the potential for treatment beyond progression warrant consideration in patient care.
Related Concept Videos
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
01:26Pharmaceutical Poisoning: Treatment Strategies
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
01:15Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:28Acute Pyelonephritis II: Diagnostic Studies and Management